

**Remarks/Arguments**

Applicants have amended the specification to provide the priority claim. The claims have been amended to remove multiple dependencies and to otherwise place the claims in an appropriate U.S. format. Specifically:

- Brackets have been removed from Claims 1 and 3.
- A typographical error in Claim 6 has been corrected wherein a period has been replaced by a semi-colon.
- Certain instances of "claim" have been replaced by "Claim" to be consistent.
- Claims 12 and 13 have been cancelled.
- Claims 14 and 15 have been added. Basis for these claims is original Claim 8.
- Claims 16 and 17 have been added. Basis for this amendment is to be found at page 34, lines 4-12 of the published PCT application.

No new matter has been added by these amendments.

The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 101243-1P US.

Respectfully submitted,

/Lucy Padget/

---

Name: Lucy Padget  
Dated: 13<sup>th</sup> April 2006  
Reg. No.: L0074  
Phone No.: 781-839-4182  
Global Intellectual Property, Patents,  
AstraZeneca R&D Boston,  
35, Gatehouse Drive,  
Waltham,  
MA 02451